The effect of anti-seizure medications on lipid values in adults with epilepsy.

Autor: Muller AL; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: amulle13@jhu.edu., Diaz-Arias L; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: ldiazar1@jh.edu., Cervenka MC; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: mcerven1@jhmi.edu., McDonald TJW; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: twill145@jhmi.edu.
Jazyk: angličtina
Zdroj: Epilepsy & behavior : E&B [Epilepsy Behav] 2023 Jul; Vol. 144, pp. 109260. Date of Electronic Publication: 2023 May 25.
DOI: 10.1016/j.yebeh.2023.109260
Abstrakt: Purpose: Certain anti-seizure medications (ASMs) adversely impact lipid values. Here, we explored the impact of ASMs on lipid values in adults with epilepsy.
Methods: A total of 228 adults with epilepsy were divided into four groups based on ASMs used: strong EIASMs, weak EIASMs, non-EIASMs, and no ASMs. Demographic information, epilepsy-specific clinical history, and lipid values were obtained through chart review.
Results: While there was no significant difference in lipid values between groups, there was a significant difference in the proportion of participants with dyslipidemia. Specifically, more participants exhibited elevated low-density lipoprotein (LDL) level in the strong EIASM group compared to the non-EIASM group (46.7% vs 18%, p < 0.05). In addition, more participants showed elevated LDL level in the weak EIASM group compared to the non-EIASM group (38% vs 18%, p < 0.05). Users of strong EIASMs showed greater odds of high LDL level (OR 5.734, p = 0.005) and high total cholesterol level (OR 4.913, p = 0.008) compared to users of non-EIASMs. When we analyzed the impact of individual ASMs used by more than 15% of the cohort on lipid levels, participants using valproic acid (VPA) showed lower high-density lipoprotein (p = 0.002) and higher triglyceride levels (p = 0.002) compared to participants not using VPA.
Conclusion: Our study demonstrated a difference in the proportion of participants with dyslipidemia between ASM groups. Thus, adults with epilepsy using EIASMs should have careful monitoring of lipid values to address the risk of cardiovascular disease.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ms. Muller has no conflicts of interest to disclose. Dr. Diaz-Arias has no conflicts of interest to disclose. Dr. Cervenka receives or has received support from The Epilepsy Foundation, The Johns Hopkins University School of Medicine Clinician Scientist Award, Nutricia, Vitaflo, The Glut1 Deficiency Foundation, The Carson Harris Foundation, Owens Family Foundation, Elaine Freeman and Johns Hopkins University Department of Neurosurgery, NIH (NINDS R01NS075020), and Army Research Laboratory. Dr. Cervenka has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Nutricia/Danone, Vitaflo/Nestlé Health Science, and The Neurology Center in Rockville, Maryland. Dr. Cervenka has received royalties from Demos/Springer Publishing Company. Dr. McDonald has received speaking honoraria from Nutricia and support from the Johns Hopkins KL2 Mentored Career Development Award (1 KL2 TR 3099-1).
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: